((4-(sec-butyl)phenyl)ethynyl)trimethylsilane

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: ((4-(sec-butyl)phenyl)ethynyl)trimethylsilane
• 英文别名: 2-(4-Butan-2-ylphenyl)ethynyl-trimethylsilane
• 化学式: C₁₅H₂₂Si
• 分子量: 230.425
• InChiKey: IFTCRZFXHJMLRF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.43
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  ((4-(sec-butyl)phenyl)ethynyl)trimethylsilane 在 palladium on activated charcoal 噻吩 、 copper(l) iodide 、 氢气 、 palladium diacetate 、 potassium carbonate 、 三乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 9.0h， 生成 2-[(Z)-2-(4-sec-Butyl-phenyl)-vinyl]-4-(2-chloro-phenyl)-9-methyl-6H-1-thia-5,7,8,9a-tetraaza-cyclopenta[e]azulene
  参考文献：
  名称：

  Thienotriazolodiazepines作为血小板活化因子拮抗剂。第2位取代基的空间限制。

  摘要：

  描述了在2-位带有取代的乙炔基的噻吩并氮杂二氮杂卓的制剂，以及相应的顺式烯烃和完全饱和的类似物。在体外和体外测试模型中，将这些化合物评估为血小板活化因子（PAF）的潜在拮抗剂。将新的噻吩并氮杂二氮杂卓与已知的相关化合物如WEB 2086（化合物6）和苯乙基衍生物27和28进行了比较。

  DOI：

  10.1021/jm00108a031
• 作为产物：
  描述：

  2-碘丁烷 、 (4-碘苯基乙炔)三甲基硅烷 在 锌 、 α,α,α-三联吡啶 、 nickel dichloride 作用下， 以 四氢呋喃 为溶剂， 反应 36.0h， 以93%的产率得到((4-(sec-butyl)phenyl)ethynyl)trimethylsilane
  参考文献：
  名称：

  Nickel-Catalyzed Negishi Cross-Coupling Reactions of Secondary Alkylzinc Halides and Aryl Iodides

  摘要：

  A general Ni-catalyzed process for the cross-coupling of secondary alkylzinc halides and aryl/heteroaryl iodides has been developed. This is the first process to overcome the isomerization and beta-hydride elimination problems that are associated with the use of secondary nucleophiles, and that have limited the analogous Pd-catalyzed systems. The impact of salt additives was also investigated. It was found that the presence of LiBF4 dramatically improves both isomeric retention and yield for challenging substrates.

  DOI：

  10.1021/ol200098d

文献信息

• Nickel-Catalyzed Negishi Cross-Coupling Reactions of Secondary Alkylzinc Halides and Aryl Iodides
  作者：Amruta Joshi-Pangu、Madhu Ganesh、Mark R. Biscoe

  DOI：10.1021/ol200098d

  日期：2011.3.4

  A general Ni-catalyzed process for the cross-coupling of secondary alkylzinc halides and aryl/heteroaryl iodides has been developed. This is the first process to overcome the isomerization and beta-hydride elimination problems that are associated with the use of secondary nucleophiles, and that have limited the analogous Pd-catalyzed systems. The impact of salt additives was also investigated. It was found that the presence of LiBF4 dramatically improves both isomeric retention and yield for challenging substrates.
• Thienotriazolodiazepines as platelet-activating factor antagonists. Steric limitations for the substituent in position 2
  作者：Armin Walser、Thomas Flynn、Carl Mason、Herman Crowley、Catherine Maresca、Margaret O'Donnell

  DOI：10.1021/jm00108a031

  日期：1991.4

  substituted ethynyl group at the 2-position, and the corresponding cis-olefins and fully saturated analogues are described. The compounds were evaluated as potential antagonists of platelet-activating factor (PAF) in in vitro and in vitro test models. The new thienotriazolodiazepines are compared with known related compounds such as WEB 2086 (compound 6) and the phenylethyl derivatives 27 and 28.

  描述了在2-位带有取代的乙炔基的噻吩并氮杂二氮杂卓的制剂，以及相应的顺式烯烃和完全饱和的类似物。在体外和体外测试模型中，将这些化合物评估为血小板活化因子（PAF）的潜在拮抗剂。将新的噻吩并氮杂二氮杂卓与已知的相关化合物如WEB 2086（化合物6）和苯乙基衍生物27和28进行了比较。